LRMR

NASDAQ open

Larimar Therapeutics

3.02 USD
▼-0.20-6.21%
盘后 2.36 0.00%
2026-11-20
市值
$330.12M
市盈率
—
EPS
-1.62
股息率
—
52 周区间
1.92 – 6.42
成交量
677.99K
Beta
0.70
目标价
14.20
52W 低 1.9252W 高 6.42
价格走势

公司简介

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.